Abstract: An arthroscopic drill for insertion into a human joint of a human body comprising an elongate body extending between a proximal end which, during use, remains external to the human body and a distal end which, when in an operative configuration, is positioned in the human joint adjacent to a target structure within the human body (e.g. preferably a joint surface); a drill bit having a proximal portion adjacent the distal end of the elongated body, the drill bit having a distal portion extending to the target structure; and an introducer sheath having a lumen with an inner diameter of at least 2 mm and a bending stiffness of approximately 0.08 Nm2, wherein the operative configuration, the elongate body extends through the introducer sheath.

Abstract: An arthroscopic drill for insertion into a human joint of a human body comprising an elongate body extending between a proximal end which, during use, remains external to the human body and a distal end which, when in an operative configuration, is positioned in the human joint adjacent to a target structure within the human body (e.g. preferably a joint surface); a drill bit having a proximal portion adjacent the distal end of the elongated body, the drill bit having a distal portion extending to the target structure; and an introducer sheath having a lumen with an inner diameter of at least 2 mm and a bending stiffness of approximately 0.08 Nm2, wherein the operative configuration, the elongate body extends through the introducer sheath.

Abstract: An arthroscopic drill for insertion into a human joint of a human body comprising an elongate body extending between a proximal end which, during use, remains external to the human body and a distal end which, when in an operative configuration, is positioned in the human joint adjacent to a target structure within the human body (e.g. preferably a joint surface); a drill bit having a proximal portion adjacent the distal end of the elongated body, the drill bit having a distal portion extending to the target structure; and an introducer sheath having a lumen with an inner diameter of at least 2 mm and a bending stiffness of approximately 0.08 Nm2, wherein the operative configuration, the elongate body extends through the introducer sheath.

Abstract: An arthroscopic drill for insertion into a human joint of a human body comprising an elongate body extending between a proximal end which, during use, remains external to the human body and a distal end which, when in an operative configuration, is positioned in the human joint adjacent to a target structure within the human body (e.g. preferably a joint surface); a drill bit having a proximal portion adjacent the distal end of the elongated body, the drill bit having a distal portion extending to the target structure; and an introducer sheath having a lumen with an inner diameter of at least 2 mm and a bending stiffness of approximately 0.08 Nm2, wherein the operative configuration, the elongate body extends through the introducer sheath.

Abstract: Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.

Abstract: Disclosed herein is an implantable fistula closure device. The device may include an expandable longitudinally segmented body including a proximal end and a distal end. The segmented body may further include a plurality of porous bodies and a connecting member operably joining together the plurality of porous bodies. The plurality of porous bodies includes a first porous body with a proximal end and a distal end and a second porous body with a proximal end and a distal end, and the connecting member operably connects the proximal end of the first porous body with the distal end of the second porous body.

Abstract: Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.

Abstract: Disclosed herein is an implantable fistula closure device. The device may include an expandable longitudinally segmented body including a proximal end and a distal end. The segmented body may further include a plurality of porous bodies and a connecting member operably joining together the plurality of porous bodies. The plurality of porous bodies includes a first porous body with a proximal end and a distal end and a second porous body with a proximal end and a distal end, and the connecting member operably connects the proximal end of the first porous body with the distal end of the second porous body.

Abstract: Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.

Abstract: Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.

Abstract: Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.